ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCAâs lead development program is intended to be a direct implementation of those ideas. Gencaro⢠(bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaroâ˘, giving Gencaro⢠the potential to be the first genetically-targeted prevention treatment for AF. AF is considered to be an epidemic cardiovascular disease and AF therapies that are safe and effective for patients with heart failure is considered a major unmet medical need. The approved therapies for the treatment or prevention AF have certain disadvantages in heart failure patients, such as toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contraindicated or have warnings in their prescribing information for such patients. We believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in heart failure patients. Source
No articles found.
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...
VBL Therapeutics is a publicly traded (NASDAQ: ...
CohBar, Inc. is a leader in the research and development of mitochondria based the...
CohBar, Inc. is a leader in the research and de...
Advaxis was founded on the vision that no one should suffer from the burdens of ca...
Advaxis was founded on the vision that no one s...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...
Organogenesis Holdings Inc. is a leading regene...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...
Join the National Investor Network and get the latest information with your interests in mind.